TNNI3 and COVID-19: Early reports indicated that an elevated level of hs-cTnI could be associated with adverse outcomes of patients with COVID-19, which can act as powerful marker in managing prognosis of patients cooperating with other biomarkers, yet more evidence is required to support this suggestion 12.